# Scinai Immunotherapeutics Ltd.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Scinai Immunotherapeutics Ltd.).

## Overview

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company with two complementary businesses: Scinai R&D, which develops inflammation and immunology therapies, and Scinai Biopharma Services, a contract development and manufacturing organization. Its therapeutic pipeline is based on NanoAbs, including VHH antibody fragments, while its CDMO operations provide analytical, process development, and clinical cGMP manufacturing services from facilities in Jerusalem and Yavne, Israel.

## Products & services

• NanoAbs VHH antibody-fragment therapeutics
• PC111 inflammation and immunology program
• IL-17 mono- and bispecific NanoAbs
• Analytical method development
• Process development and technology transfer
• Clinical cGMP manufacturing

- **CDMO services** (80%) — Analytical, process development, technology transfer, and clinical cGMP manufacturing for biotech and pharmaceutical customers.
- **NanoAbs therapeutics** (10%) — Preclinical and development-stage immunology programs using VHH antibody fragments and advanced antibody formats.
- **PC111 program** (5%) — A therapeutic development program targeting inflammation and immunology applications.
- **IL-17 programs** (5%) — Local intradermal and systemic IL-17 NanoAbs, including mono- and bispecific formats.

- NanoAbs based on VHH antibody fragments
- PC111 inflammation and immunology program
- Local and systemic IL-17 NanoAb programs
- Analytical method development for biotech clients
- Process development and technology transfer
- Clinical cGMP manufacturing services

## Customers

Scinai’s CDMO customers are biotechnology and pharmaceutical companies seeking outsourced analytical development, process development, clinical manufacturing, and related technology-transfer support. The customer base can include early-stage developers that need flexible development capacity as well as larger pharmaceutical partners requiring a pathway from early development to later-stage supply. Scinai’s R&D business serves patients and healthcare markets indirectly through potential licensing, partnering, or commercialization of its immunology programs rather than through direct product sales.

- **Biotechnology companies** (primary) — Buy analytical, process development, and clinical manufacturing services to advance drug candidates without building all capabilities internally.
- **Pharmaceutical companies** (primary) — Use CDMO capabilities for development, technology transfer, and clinical supply across biologic and other modalities.
- **Emerging drug developers** (secondary) — Seek flexible, boutique support for early-stage development and preparation for clinical manufacturing.
- **Strategic licensing and development partners** (emerging) — May partner around PC111, IL-17 programs, and the broader NanoAbs platform to access immunology assets.

- Biotechnology companies needing outsourced development capacity
- Pharmaceutical companies requiring clinical cGMP manufacturing
- Early-stage developers seeking analytical and process support
- Drug developers needing recombinant or antibody capabilities
- Potential partners for NanoAbs-based immunology programs

## Geography

Scinai is a U.S.-listed Israeli biopharmaceutical company whose operating infrastructure is concentrated in Israel. Scinai Biopharma Services operates facilities in Jerusalem and Yavne, while its CDMO customer base is described as international. No country-level revenue percentages or authoritative revenue-by-geography data are provided in the available reports.

- Jerusalem hosts part of the CDMO operating footprint
- Yavne provides additional development and manufacturing capacity
- Israel is the core location for facilities and operations
- CDMO services are marketed to biotech clients worldwide
- NASDAQ listing gives the company U.S. capital-market access

## Strategy

Scinai’s strategy is to combine a revenue-generating CDMO platform with internally developed immunology therapeutics. The acquisition of the Recipharm Israel site and commercial collaboration with Recipharm are intended to expand capabilities across recombinant proteins, small molecules, peptides, antibodies, and oligonucleotides while creating a route from early development to later-stage supply. In parallel, Scinai is advancing PC111 and local and systemic IL-17 NanoAb programs while developing the broader NanoAbs platform.

- **Scale the integrated CDMO platform** (medium-term) — Broader capabilities can increase the addressable customer base and support clients through more development stages.
- **Advance NanoAbs immunology programs** (medium-term) — Successful development could create proprietary therapeutic assets beyond service revenue.
- **Secure non-dilutive and strategic development support** (short-term) — Grants and partnerships can help fund R&D and validate programs while reducing reliance on internal capital.

- Expand CDMO capabilities across multiple drug modalities
- Use Recipharm collaboration to support later-stage supply
- Convert early development work into repeat manufacturing demand
- Advance PC111 and IL-17 immunology programs
- Develop NanoAbs for mono- and multi-specific formats
- Pursue grants and external funding for R&D programs

## Risks

Scinai faces the execution risk of integrating and commercializing an expanded CDMO footprint while building sufficient customer demand to utilize its facilities. Its therapeutic programs remain exposed to preclinical and clinical development failure, regulatory uncertainty, funding needs, and competition from established biologic platforms. Concentration of operating assets in Israel also creates geographic, security, supply-chain, and foreign-exchange exposure.

- **CDMO customer concentration and demand risk** [high] — The service business depends on project awards, customer development timelines, and facility utilization.
- **Acquisition and integration execution** [high] — The expanded platform requires integration of facilities, processes, employees, and commercial workflows with Recipharm.
- **Therapeutic development failure** [critical] — PC111 and IL-17 NanoAb programs may fail to demonstrate safety, efficacy, or commercial differentiation.
- **Regulatory and quality compliance** [high] — Clinical cGMP manufacturing and biologic development require compliance with demanding regulatory and quality standards.
- **Israel geopolitical and operational exposure** [high] — Facilities in Jerusalem and Yavne may be affected by security conditions, workforce disruption, logistics, or supplier interruptions.
- **Foreign-exchange exposure** [medium] — Israeli operating activities and reporting in U.S. dollars can produce translation volatility, as shown by foreign currency translation adjustments.

- CDMO growth depends on winning and retaining biotech customers
- Facility integration may create execution and utilization risks
- NanoAbs programs may fail in development or clinical testing
- Biologic manufacturing requires costly quality and regulatory compliance
- Israel concentration creates security and operational exposure
- Small-company funding needs may constrain R&D progress

## Accounting

CDMO revenue recognition depends on the terms and progress of analytical, development, manufacturing, and technology-transfer contracts, which can create timing differences between work performed and invoicing. The Recipharm Israel acquisition introduces purchase accounting judgments, including asset valuation and the recognition of any bargain purchase gain, while operating leases affect both assets and liabilities. Foreign-currency translation from Israeli operations can affect comprehensive income even when it does not represent operating performance.

- **CDMO revenue recognition** — Affects quarterly revenue timing, contract assets, receivables, and gross profit.
- **Business combination accounting** — Can create depreciation, amortization, goodwill, or a bargain purchase gain.
- **Lease accounting** — Changes reported assets, liabilities, and lease-related operating expenses.
- **Foreign-currency translation** — Translation movements flow through other comprehensive income, as reflected by the reported adjustment.
- **Research and development accounting** — Program timing and grant recognition can influence operating losses and period comparability.

- CDMO contract milestones can shift revenue between periods
- Work-in-progress and contract receivables require estimation
- Acquisition accounting may create goodwill or bargain gains
- Operating leases materially affect assets and liabilities
- Israeli shekel translation affects comprehensive income
- R&D capitalization and expense treatment affects comparability

---

*Last updated: 2026-09-08T05:51:43.461350+00:00*